At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
moderate- or high-intensity statin/ rosuvastatindrug
Likely dose
moderate- or high-intensity statin/ rosuvastatin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
In Brief
A Phase 4 clinical trial evaluating moderate- or high-intensity statin/ rosuvastatin for Lipid Disorder. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipid Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
First PostedFeb 2023
Enrollment StartMar 2023
Primary CompletionJun 2023
Study CompletionJul 2023
TodayJul 2026
First PostedFeb 24, 2023
Enrollment StartMar 8, 2023
Primary CompletionJun 1, 2023
Study CompletionJul 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.4 years ago
Interventions
moderate- or high-intensity statin/ rosuvastatindrug
moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)